Poorest WTO members win new patent-rule waiver

Jun 11, 2013

The globe's poorest nations have won an eight-year extension of a waiver on intellectual property rules, but still need to hold talks on the vexed issue of pharmaceutical patents, World Trade Organization officials said Tuesday.

A session of the 159-nation WTO's TRIPS Council—standing for trade-related aspects of —ruled that the waiver for 34 countries can now run until July 1, 2021.

"The agreement reached by members makes very clear that we can come together and get things done," WTO chief Pascal Lamy told the council, saying that it provided valuable lessons as member states struggle to revive the so-called Doha Round of liberalisation talks.

The TRIPS agreement, in force since 1995, requires WTO member states to legislate and enforce minimum standards for the protection of intellectual property in order to boost confidence in global commerce.

But critics said that such rules would be tough to bring in and police in the world's poorest nations, whose failure to fall into line could thereby shut them out of trade sectors and hamper their development.

With the stated goal of the Doha Round, launched at a summit in Qatar in 2001, to harness to help boost , WTO members that year agreed on a waiver.

Initially due to run out in 2006, it was extended to 2013.

Separate rules within the TRIPS agreement apply to pharmaceuticals, where a current waiver runs out in 2016, meaning talks will be needed if the countries are to win a new extension.

The pharmaceutical rules within TRIPS are the focus of intense criticism from health campaigners, who charge that they make it tough for countries without a waiver to get access to affordable medicines and are seeking an open-ended escape clause for the poorest nations.

Explore further: Sony forecasts $2B loss as smartphones lag (Update)

add to favorites email to friend print save as pdf

Related Stories

Bayer 'disappointed' after losing India patent fight

Sep 26, 2012

Pharmaceutical giant Bayer AG on Wednesday said it was "disappointed" with an Indian ruling that allows a local firm to produce a cheaper copy of its patented drug Nexavar for liver and lung cancer.

Bayer challenges India cancer drug ruling

May 06, 2012

German pharmaceutical giant Bayer AG has challenged a ground-breaking Indian ruling that allowed a local firm to produce a vastly cheaper copy of its patented drug for kidney and liver cancer.

WTO chief plays down China rare earth row

Mar 16, 2012

The head of the World Trade Organization on Friday played down a dispute over China's controls on exports of rare earth minerals, saying it was unlikely to escalate into a trade war.

Recommended for you

Sony forecasts $2B loss as smartphones lag (Update)

14 hours ago

Sony expects its annual loss to swell to $2 billion and has canceled dividends for the first time in more than half a century after writing down the value of its troubled smartphone business.

Alibaba post-IPO structure gives insiders control

14 hours ago

Control over Alibaba Group will stay in the hands of founder Jack Ma and other company veterans after the Chinese e-commerce giant goes public on the New York Stock Exchange in a record busting share sale.

User comments : 0